多系统性缩症的消化不良是否对利沃多巴有反应? 一项回顾性研究的结果
Florin Gandor1,2,3,4, Luise Berger2,3, Vera Jäger2
1Macquarie University Hospital, Department of Neurology, Macquarie University, Faculty of Medicine, Health and Human Sciences, Sydney, New South Wales, Australia.
Movement disorders clinical practice
|September 12, 2025
概括
在多个系统缩 (MSA) 中吞困难的利沃多巴反应有显著的差异. 虽然一些患者可能会看到改善,但许多人没有,这表明需要针对MSA缺食症进行个性化治疗方法.
科学领域:
- 神经学 神经学
- 胃肠病学 胃肠病学
背景情况:
- 缺食症是多重系统缩 (MSA) 的一个重要的临床问题.
- 目前与MSA相关的食障碍的治疗选择有限.
研究的目的:
- 系统地评估MSA患者对Levodopa治疗的消化不良反应的反应.
- 为了比较吞功能在勒沃多巴给药前和后.
主要方法:
- 19名患有MSA的患者接受了内镜吞评估 (FEES).
- 通过使用适应的协议,对莱沃多巴"关闭"和"启动"状态进行了评估.
- 结果在各州之间进行了比较,并与疾病和人口因素相关联.
主要成果:
- 在MSA患者中,乐伏多巴对运动障碍的反应很差.
- 缺食症的严重程度各不相同,一些患者在泄漏和吸收方面显著改善,而大多数患者保持不变或恶化.
- 观察到泄漏的严重程度降低,但喉残留物,透和吸入在很大程度上保持不变.
- 不规则的关节软骨运动 (iACM) 在所有患者中都很普遍,不管他们是否服用了乐伏多巴.
结论:
- 在与MSA相关的食障碍症中,levodopa的反应非常可变.
- 个别患者的评估对于定制MSA的消化障碍疗法至关重要.
- 需要进一步研究MSA失足症的非药物干预措施.
- 不规则的关节软骨运动 (iACM) 是MSA的一个常见发现.
相关概念视频
Parkinson's Disease: Treatment
995
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
995
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K


